A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Key facts

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Intervention

AK105 Injection(drug)

Enrollment

648 enrolled

Eligibility

18-75 years · All sexes

Timeline

2020 – 2026

Study locations (30)

• The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
• Anhui Provincial Hospital, Hefei, Anhui, China
• The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
• Anhui Provincial Cancer Hospital, Hefei, Anhui, China
• Beijing Ditan Hospital.Capital Medical University, Beijing, Beijing Municipality, China
• Beijing YouAn Hospital.Capital Medical University, Beijing, Beijing Municipality, China
• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
• Chinese Pla General Hospital, Beijing, Beijing Municipality, China
• Beijing Tsinghua Changgung Hospital, Beijing, Beijing Municipality, China
• Beijing Luhe Hospital.Capital Medical University, Beijing, Beijing Municipality, China
• The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• Chongqing University Three Gorges Hospital, Chongqing, Chongqing Municipality, China
• The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
• Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
• The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07521852
  A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
  TaiRx, Inc.
• RECRUITINGPHASE2NCT07504471
  Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
  Ruijin Hospital
• RECRUITINGNCT07295275
  Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
  West China Hospital
• RECRUITINGPHASE2NCT07324824
  Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
  Sun Yat-sen University
• RECRUITINGEARLY PHASE1NCT07193862
  Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
  Northwell Health
• RECRUITINGPHASE1, PHASE2NCT07282184
  Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
  Tongji Hospital
• RECRUITINGNCT07170345
  Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
  Chinese Academy of Sciences
• RECRUITINGPHASE2NCT07099274
  Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital

See all trials for Fibrolamellar hepatocellular carcinoma →